SUMMIT THERAPEUTICS RECEIVES REGULATORY APPROVAL TO INITIATE PhaseOut DMD, A PHASE 2 CLINICAL TRIAL OF SMT C1100 IN PATIENTS WITH DMD January 21, 2016 - Posted in Research Articles